Cargando…

Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose

The BNT162b2 vaccine induces neutralizing activity (NA) in serum, but no data are available on whether a third-dose activates specific-immunity within the oral mucosa, representing the primary route of viral-entry. To carefully address this issue, we investigated if such immunity is boosted by SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garziano, Micaela, Utyro, Olga, Strizzi, Sergio, Vanetti, Claudia, Saulle, Irma, Conforti, Chiara, Cicilano, Federica, Ardizzone, Francesco, Cappelletti, Gioia, Clerici, Mario, Limanaqi, Fiona, Biasin, Mara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693379/ https://www.ncbi.nlm.nih.gov/pubmed/36430815 http://dx.doi.org/10.3390/ijms232214341

Ejemplares similares

Dopamine Reduces SARS-CoV-2 Replication In Vitro through Downregulation of D2 Receptors and Upregulation of Type-I Interferons
por: Limanaqi, Fiona, et al.
Publicado: (2022)

Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees
por: Garziano, Micaela, et al.
Publicado: (2022)

Salivary miRNA Profiles in COVID-19 Patients with Different Disease Severities
por: Saulle, Irma, et al.
Publicado: (2023)

MiRNA Profiling in Plasma and Placenta of SARS-CoV-2-Infected Pregnant Women
por: Saulle, Irma, et al.
Publicado: (2021)

A New ERAP2/Iso3 Isoform Expression Is Triggered by Different Microbial Stimuli in Human Cells. Could It Play a Role in the Modulation of SARS-CoV-2 Infection?
por: Saulle, Irma, et al.
Publicado: (2020)

An Overview on ERAP Roles in Infectious Diseases
por: Saulle, Irma, et al.
Publicado: (2020)

Antigen presentation in SARS-CoV-2 infection: the role of class I HLA and ERAP polymorphisms
por: Saulle, Irma, et al.
Publicado: (2021)

Simplexviruses Successfully Adapt to Their Host by Fine-Tuning Immune Responses
por: Mozzi, Alessandra, et al.
Publicado: (2022)

UV and violet light can Neutralize SARS-CoV-2 Infectivity
por: Biasin, Mara, et al.
Publicado: (2022)

The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide
por: Fenizia, Claudio, et al.
Publicado: (2021)

SARS-CoV-2 vertical transmission during the first trimester of pregnancy in asymptomatic women
por: Fenizia, Claudio, et al.
Publicado: (2022)

Unlikely SARS-CoV-2 Transmission During Vaginal Delivery
por: Fenizia, Claudio, et al.
Publicado: (2021)

A Regulatory Polymorphism in HAVCR2 Modulates Susceptibility to HIV-1 Infection
por: Sironi, Manuela, et al.
Publicado: (2014)

Pregnant Women Develop a Specific Immunological Long-Lived Memory Against SARS-COV-2
por: Fenizia, Claudio, et al.
Publicado: (2022)

Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia
por: Esposito, Susanna, et al.
Publicado: (2015)

Anti-Inflammatory Effects of Immunostimulation in Patients with COVID-19 Pneumonia
por: Santus, Pierachille, et al.
Publicado: (2021)

Immunological Characterization of HIV and SARS-CoV-2 Coinfected Young Individuals
por: Vanetti, Claudia, et al.
Publicado: (2021)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature
por: Torretta, Enrica, et al.
Publicado: (2021)

Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine
por: Sheehan, Jared, et al.
Publicado: (2023)

High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals
por: Aguilar-Jimenez, Wbeimar, et al.
Publicado: (2017)

Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication
por: Trabattoni, Daria, et al.
Publicado: (2016)

The Immunological Profile of SARS-CoV-2 Infection in Children Is Linked to Clinical Severity and Age
por: Vanetti, Claudia, et al.
Publicado: (2023)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
por: Darwich, Abbass, et al.
Publicado: (2022)

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis
por: Dekervel, Marine, et al.
Publicado: (2021)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Acute myocarditis after a third dose of the BNT162b2 COVID-19 vaccine
por: Fosch, Xavier, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Acute Myopericarditis After the Third Vaccination of BNT162b2 in a Middle-Aged Man
por: Nakawatase, Satoshi, et al.
Publicado: (2022)

Reply to Mungmunpuntipantip and Wiwanitkit: CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
por: Vargas-Herrera, Natalia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_41kfnfhfupv6hoaj5472abrvss